anewmeds.com (WENA) - Long-Term Liabilities to Capital

Anew Medical, Inc. (WENA) is developing innovative gene therapy methods to combat Alzheimer's disease, aiming to ensure brain longevity. However, the business faces threats from a lack of revenue, potential research failures, and a dependence on external investments. The current metric stands at 0.00, highlighting a liquidity deficit. This price chart below clearly demonstrates the financial condition of this biotech startup.

This indicator assesses the degree of the company's reliance on borrowed funds with a repayment horizon of more than one year. Analyzing the long-term financial leverage ratio allows for the determination of the actual debt load relative to equity. The metric is calculated by dividing the total amount of long-term loans by the total value of assets minus liabilities. For Anew Medical, Inc. (WENA), a low debt level is critically important when capitalizing unique patents in ALS therapy. This ensures financial stability during the development of protected biotechnological innovations.